Skip to main navigation Skip to search Skip to main content

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

  • S Halford
  • , D Yip
  • , C Karapetis
  • , A Strickland
  • , A. Steger
  • , H T Khawaja
  • , P Harper

    Research output: Contribution to journalArticlepeer-review

    53 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)1399-1402
    Number of pages4
    JournalAnnals of Oncology
    Volume12
    Issue number10
    Publication statusPublished - 2001

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Cite this